Your report is to commercialise one of these processes and launch a new, more expensive, but orally bioavailable form of insulin.
Your brief is to objectively assess the project and address the following issues in your report to the Board
1- Executive Summary:
Summarise the project background, benefits, additional research required, suggested process model and treatment of major risks.
Conclude with overall recommendation as to the project’s priority.
2- Business Case:
Describe the client and the background for the project Financial and/or strategic justification
Project success criteria. How will the client know the project was successful?
How can the client ensure that the expected benefits are realised?
Is this project part of an overall program or portfolio?
3- Process Model:Is an agile methodology recommended, or a standard waterfall approach? Is any iteration planned?
Provide a high level work breakdown structure or process model for the project.
4- Risk Management Plan:
Client wants to see ONLY ‘project specific’ risks. They are aware of the generic risks that affect virtu ally all biotech projects (sudi resignation of key project members, delays from suppliers, equipment failure, lack of test subjects etc.)
Tables should include each major risk identifying the source, event, consequence, probability, existing control(s) and initial risk rating.
Another table should include the risk treatment plan for each risk with an unacceptable rating including the cost justification and effectiveness (e.g. residual risk rating).
Not all risks can be treated! What are the risks that the Board will be forced to accept?
5- Condusion:
In the Consultant’s opinion how does this project rate for the client?
Should the client focus on other opportunities that have a better return on investment or a lower overall risk?
If this project is highly recommended, what are the key factors which have persuaded the Consultant?
0 comments:
Post a Comment